Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab.

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver Cancer Pub Date : 2022-12-01 DOI:10.1159/000526388

Kei Endo, Hidekatsu Kuroda, Takayoshi Oikawa, Yuma Ito, Tamami Abe, Youhei Kooka, Keisuke Kakisaka, Akio Miyasaka, Tamotsu Sugai, Takayuki Matsumoto

引用次数: 2

Abstract

No abstract due to Letter.

Abstract Image

查看原文本刊更多论文

不可切除肝细胞癌中免疫检查点抑制剂相关肺炎:阿特唑单抗联合贝伐单抗治疗2例死亡病例

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver Cancer Medicine-Oncology

CiteScore

20.80

自引率

7.20%

发文量

审稿时长

16 weeks

期刊介绍： Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.